Israeli fertility company Fairtility has announced the launch of CHLOE OQ, a tool aimed at fertility preservation, at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Copenhagen today. The newly unveiled tool provides Oocyte Quality Insights, predicting the potential of an oocyte (egg cell) to develop into the blastocyst stage after fertilization, a crucial aspect often described as a “statistical gamble” in fertility treatment.
About a year ago Fairtility earned CE certification for CHLOE EQ, which brings AI insight to embryo quality assessment. CHLOE OQ, which has also received CE certification, now brings AI-powered assessment to oocyte evaluation, replacing subjective decision-making with personalized, data-driven analysis. It stands to enhance decision-making across three key areas: egg freezing, egg donation, and IVF treatment.
“Adding oocyte analysis broadens CHLOE’s core technology capabilities, extending beyond embryo assessment for IVF. CHLOE OQ now provides decision support for fertility preservation, egg donation, and female-factor infertility in IVF treatment. This expansion allows us to assist a larger population seeking to secure their reproductive futures,” stated Eran Eshed, CEO and Co-Founder of Fairtility. “While we can’t halt the passage of time and the consequent decline in oocyte quality, we can effectively freeze it. With CHLOE OQ, patients, through their fertility care team, can gain transparency into their oocytes’ viability, enabling proactive management of their reproductive health and facilitating well-informed decisions based on biological data.”
Dr. Cristina Hickman, Chief Clinical Officer of Fairtility, adds: “An embryologist’s assessment of fertility potential involves understanding three factors: sperm, oocytes and embryos. We can evaluate the viability of embryos and understand sperm quality. However, assessing oocyte quality has remained a statistical gamble. When looking at a seemingly ‘good’ oocyte, we can’t really identify which one will become a blast after fertilization. CHLOE OQ helps us fill the critical gap, providing evidence-based viability predictions for the evaluation of oocytes. This will help clinicians to provide transparency to patients while discussing the potential of frozen oocytes for fertility preservation, the potential reasons for a failed IVF cycle, or when assessing and allocating donor eggs.”
